Attenuated African swine fever virus vaccine based in the deletion of MGF genes

Patent metadata

Field	Value
Publication number	US-9528094-B2
Application number	US-201414537248-A
Country	US
Kind code	B2
Filing date	Nov 10, 2014
Priority date	Nov 10, 2014
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs. Control of ASF has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. Among viral genes reported to be involved in virulence are components of the multi gene family (MGF). Here we report the construction of a recombinant ΔMGF virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G ΔMGF administered intramuscularly (IM) to swine at either 10 2 or 10 4 HAD 50 are completely attenuated; the inoculated animals are completely asymptomatic. Animals infected with 10 2 or 10 4 HAD50 of ASFV-G ΔMGF are protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.

First claim

We claim:

1. A recombinant African Swine Fever Virus—Georgia 2007 isolate (ASFV-G) mutant virus, ASFV-G ΔMGF, wherein the ASFV-G ΔAMGF mutant virus genome comprises SEQ ID NO: 2.

2. A vaccine composition against ASFV-G comprising the recombinant SFV-G ΔMGF virus according to claim 1 .

3. A method for the protection of swine against African Swine Fever Virus—Georgia 2007 isolate (ASFV-G), comprising administering to swine a live attenuated ASFV-G ΔMGF vaccine comprising a recombinant mutant ASFV-G ΔMGF virus according to claim 1 in an amount effective to protect said swine from clinical ASF-G.

4. The method of claim 3 wherein the amount effective to protect said swine from clinical ASF-G is a vaccine comprising 10 2 -10 4 HAD 50 of ASFV-G ΔMGF virus.

Assignees

• Us Agriculture
• Univ Connecticut

Inventors

• Borca Manuel V
• Holinka-Patterson Lauren G
• O'Donnell Vivian K
• Risatti Guillermo S
• Gladu Douglas

Classifications

• A61K39/12

  Viral antigens · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• C12Q1/701

  Specific hybridization probes · CPC title

• C12N2710/12034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title